eMedicine Specialties > Physical Medicine and Rehabilitation > Myopathy

Corticosteroid-Induced Myopathy: Follow-up

Author: Steve S Lim, MD, Consulting Staff, Department of Physical Medicine and Rehabilitation, St Clare's Hospital of Dover
Coauthor(s): Patrick M Foye, MD, FAAPMR, FAAEM, Associate Professor of Physical Medicine and Rehabilitation, Co-Director of Musculoskeletal Fellowship, Co-Director of Back Pain Clinic, Director of Coccyx Pain Service (Tailbone Pain Service: www.TailboneDoctor.com), University of Medicine and Dentistry of New Jersey, New Jersey Medical School
Contributor Information and Disclosures

Updated: Sep 28, 2009

Follow-up

Deterrence/Prevention

  • Consider the judicious use of steroids.

Complications

  • Although prior studies have reported full motor recovery, some patients may be left with varying degrees of residual weakness.

Prognosis

  • In chronic (classic) steroid myopathy, recovery from weakness may take weeks to months following discontinuation or dose reduction of the corticosteroid.
  • In acute steroid myopathy, recovery may be prolonged (>6 mo).

Patient Education

  • Inform patients of the potential of development of myopathy when starting high-dose or long-term corticosteroid therapy.

Miscellaneous

Medicolegal Pitfalls

  • The main potential pitfall in diagnosing steroid myopathy relates to patients with polymyositis/dermatomyositis, which typically is treated with corticosteroids. The main symptom of polymyositis/dermatomyositis is proximal upper and lower extremity weakness. When these patients, while being treated with corticosteroids, develop increasing weakness, it can be difficult to determine whether the weakness is secondary to the polymyositis or to steroid myopathy.
  • Laboratory studies can aid in differentiating between the 2 conditions. Creatine kinase typically is elevated significantly in polymyositis/dermatomyositis. In steroid myopathy, it typically has been described that, although there is elevated urinary creatinine excretion, the serum creatine kinase is not significantly elevated.1,13 However, some studies have reported elevations of creatine kinase in some cases of the previously described acute form of steroid myopathy.
  • On electrodiagnostic study, polymyositis typically demonstrates normal NCS results, as, commonly, does steroid myopathy. On EMG study, however, polymyositis demonstrates abnormal spontaneous activity and increased polyphasic waveforms with short durations. The classic form of steroid myopathy has been described as not demonstrating significantly abnormal EMG findings. Again, some studies have described an acute form of steroid myopathy that can demonstrate abnormal spontaneous activity, an early recruitment pattern, and small, polyphasic waveforms.12,13
  • The initial recommendation is to decrease or discontinue the use of the corticosteroid.16 If the weakness improves, then steroid myopathy is the most likely diagnosis. If the weakness persists or worsens, then the most likely diagnosis is worsening of the polymyositis.
 
Acknowledgments

Debra Ibrahim, 4th year medical student, New York College of Osteopathic Medicine, class of 2008, assisted with the revision of this manuscript.

Evish Kamrava, 4th year medical student, St. George's University School of Medicine, class of 2009, assisted with the revision of this manuscript.



More on Corticosteroid-Induced Myopathy

Overview: Corticosteroid-Induced Myopathy
Differential Diagnoses & Workup: Corticosteroid-Induced Myopathy
Treatment & Medication: Corticosteroid-Induced Myopathy
Follow-up: Corticosteroid-Induced Myopathy
References
Further Reading
[ CLOSE WINDOW ]

References

  1. Askari A, Vignos PJ Jr, Moskowitz RW. Steroid myopathy in connective tissue disease. Am J Med. Oct 1976;61(4):485-92. [Medline].

  2. Yamaguchi M, Niimi A, Minakuchi M, et al. Corticosteroid-induced myopathy mimicking therapy-resistant asthma. Ann Allergy Asthma Immunol. Oct 2007;99(4):371-4. [Medline].

  3. Lacomis D, Smith TW, Chad DA. Acute myopathy and neuropathy in status asthmaticus: case report and literature review. Muscle Nerve. Jan 1993;16(1):84-90. [Medline].

  4. Inder WJ, Jang C, Obeyesekere VR, et al. Dexamethasone administration inhibits skeletal muscle expression of the androgen receptor and IGF-1 - implications for steroid-induced myopathy. Clin Endocrinol (Oxf). Aug 4 2009;[Medline].

  5. Betters JL, Long JH, Howe KS, et al. Nitric oxide reverses prednisolone-induced inactivation of muscle satellite cells. Muscle Nerve. Feb 2008;37(2):203-9. [Medline].

  6. Kumar S. Steroid-induced myopathy following a single oral dose of prednisolone. Neurol India. Dec 2003;51(4):554-6. [Medline]. [Full Text].

  7. Dekhuijzen PN, Decramer M. Steroid-induced myopathy and its significance to respiratory disease: a known disease rediscovered. Eur Respir J. Sep 1992;5(8):997-1003. [Medline].

  8. Borba A, Guil D, Naveso G, et al. [Oral steroids effects on the respiratory muscles function in severe asthmatic patients.]. Rev Port Pneumol. Dec 2006;12(6 Suppl 1):39-40. [Medline].

  9. Stanton AE, Sellars C, Mackenzie K, et al. Perceived vocal morbidity in a problem asthma clinic. J Laryngol Otol. Jan 2009;123(1):96-102. [Medline].

  10. Afifi AK, Bergman RA, Harvey JC. Steroid myopathy. Clinical, histologic and cytologic observations. Johns Hopkins Med J. Oct 1968;123(4):158-73. [Medline].

  11. Danon MJ, Schliselfeld LH. Study of skeletal muscle glycogenolysis and glycolysis in chronic steroid myopathy, non-steroid histochemical type-2 fiber atrophy, and denervation. Clin Biochem. Jan 2007;40(1-2):46-51. [Medline].

  12. Dumitru D. Myopathies. In: Electrodiagnostic Medicine. San Antonio, Tex: University of Texas; 1995:1031-129.

  13. Hanson P, Dive A, Brucher JM, et al. Acute corticosteroid myopathy in intensive care patients. Muscle Nerve. Nov 1997;20(11):1371-80. [Medline].

  14. Ahlbeck K, Fredriksson K, Rooyackers O, et al. Signs of critical illness polyneuropathy and myopathy can be seen early in the ICU course. Acta Anaesthesiol Scand. Jul 2009;53(6):717-23. [Medline].

  15. Uchikawa K, Takahashi H, Hase K, et al. Strenuous exercise-induced alterations of muscle fiber cross-sectional area and fiber-type distribution in steroid myopathy rats. Am J Phys Med Rehabil. Feb 2008;87(2):126-33. [Medline].

  16. Batchelor TT, Taylor LP, Thaler HT, et al. Steroid myopathy in cancer patients. Neurology. May 1997;48(5):1234-8. [Medline].

  17. Menezes LG, Sobreira C, Neder L, et al. Creatine supplementation attenuates corticosteroid-induced muscle wasting and impairment of exercise performance in rats. J Appl Physiol. Feb 2007;102(2):698-703. [Medline]. [Full Text].

  18. Hollister JR. The untoward effects of steroid treatment on the musculoskeletal system and what to do about them. J Asthma. 1992;29(6):363-8. [Medline].

[ CLOSE WINDOW ]

Keywords

corticosteroid-induced myopathy, myopathy, steroid, steroids, corticosteroid, corticosteroids, polymyositis, dermatomyositis, adrenal tumor, adrenal tumors, hydrocortisone, prednisone, triamcinolone, dexamethasone, steroid myopathy, acute steroid myopathy, chronic steroid myopathy, critical illness myopathy, excess endogenous corticosteroid production, excess exogenous corticosteroid production, asthma, steroid treatment for asthma, steroid treatment for polymyositis, steroid treatment for connective tissue disorders, steroid treatment for rheumatoid arthritis, fluorinated steroids, nonfluorinated steroids, prolonged administration of prednisone

[ CLOSE WINDOW ]

Contributor Information and Disclosures

Author

Steve S Lim, MD, Consulting Staff, Department of Physical Medicine and Rehabilitation, St Clare's Hospital of Dover
Steve S Lim, MD is a member of the following medical societies: American Academy of Physical Medicine and Rehabilitation
Disclosure: Nothing to disclose.

Coauthor(s)

Patrick M Foye, MD, FAAPMR, FAAEM, Associate Professor of Physical Medicine and Rehabilitation, Co-Director of Musculoskeletal Fellowship, Co-Director of Back Pain Clinic, Director of Coccyx Pain Service (Tailbone Pain Service: www.TailboneDoctor.com), University of Medicine and Dentistry of New Jersey, New Jersey Medical School
Patrick M Foye, MD, FAAPMR, FAAEM is a member of the following medical societies: American Academy of Physical Medicine and Rehabilitation, American Association of Neuromuscular and Electrodiagnostic Medicine, Association of Academic Physiatrists, and International Spine Intervention Society
Disclosure: Nothing to disclose.

Medical Editor

Patrick J Potter, MD, FRCP(C), Associate Professor, Physical Medicine and Rehabilitation, The University of Western Ontario; Consulting Staff, Department of Physical Medicine and Rehabilitation, St Joseph's Health Care Centre
Patrick J Potter, MD, FRCP(C) is a member of the following medical societies: American Paraplegia Society, Canadian Association of Physical Medicine and Rehabilitation, Canadian Medical Association, College of Physicians and Surgeons of Ontario, Ontario Medical Association, and Royal College of Physicians and Surgeons of Canada
Disclosure: Nothing to disclose.

Pharmacy Editor

Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine
Disclosure: eMedicine Salary Employment

Managing Editor

Kat Kolaski, MD, Assistant Professor, Departments of Orthopedic Surgery and Pediatrics, Wake Forest University School of Medicine
Kat Kolaski, MD is a member of the following medical societies: American Academy for Cerebral Palsy and Developmental Medicine and American Academy of Physical Medicine and Rehabilitation
Disclosure: Nothing to disclose.

CME Editor

Kelly L Allen, MD, Regional Medical Director, IMX-Medical Management Services
Disclosure: Nothing to disclose.

Chief Editor

Denise I Campagnolo, MD, MS, Director of Multiple Sclerosis Clinical Research and Staff Physiatrist, Barrow Neurology Clinics, St Joseph's Hospital and Medical Center; Investigator for Barrow Neurology Clinics; Director, NARCOMS Project for Consortium of MS Centers
Denise I Campagnolo, MD, MS is a member of the following medical societies: Alpha Omega Alpha, American Association of Neuromuscular and Electrodiagnostic Medicine, American Paraplegia Society, Association of Academic Physiatrists, and Consortium of Multiple Sclerosis Centers
Disclosure: Teva Neuroscience Honoraria Speaking and teaching; Serono-Pfizer Honoraria Speaking and teaching; Genzyme Corporation Grant/research funds investigator; Biogen Idec Grant/research funds investigator; Genentech, Inc Grant/research funds investigator; Eli Lilly & Company Grant/research funds Novaritis; Novaritis  Novaritis; MSDx LLC Grant/research funds investigator; BioMS Technology Corp Grant/research funds investigator; Avanir Pharmaceuticals Grant/research funds investigator

 
 
HONcode

We subscribe to the
HONcode principles of the
Health On the Net Foundation

All material on this website is protected by copyright, Copyright© 1994- by Medscape.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.